Observational studyJournal of clinical hypertension (Greenwich, Conn.)2017
Low Levels of MicroRNA-21 Are a Marker of Reduced Arterial Stiffness in Well-Controlled Hypertension.
Observational study in Journal of clinical hypertension (Greenwich, Conn.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 30 citations in OpenAlex.
- MicroRNAs in Pediatric Primary Hypertension: Promising Biomarkers or Context-Dependent Regulators?-A Narrative Review.Biomolecules · 2026Review
- A catalytic hairpin amplification platform triggered by near-infrared light and logic assembly for sensitive detection of microRNAs.Nanoscale advances · 2026Article
- ATHENA Study - The Role of Circulating Plasma MicroRNAs in Paediatric Patients with Untreated Primary Hypertension: Baseline Expression and Exercise-Induced Changes.Kidney & blood pressure research · 2026Observational
- Cardiovascular risk factors and modern therapeutic strategies in children and adolescents with type 1 diabetes to prevent future diabetic angiopathy in the era of innovative miRNAs biomarkers.Frontiers in endocrinology · 2025Review
- Article
- A Machine Learning Model Based on microRNAs for the Diagnosis of Essential Hypertension.Non-coding RNA · 2023Article
- Insights Into Platelet-Derived MicroRNAs in Cardiovascular and Oncologic Diseases: Potential Predictor and Therapeutic Target.Frontiers in cardiovascular medicine · 2022Review
- Degradation of Premature-miR-181b by the Translin/Trax RNase Increases Vascular Smooth Muscle Cell Stiffness.Hypertension (Dallas, Tex. : 1979) · 2021Article
- Arterial Stiffness in Type 1 Diabetes: The Case for the Arterial Wall Itself as a Target Organ.Journal of clinical medicine · 2021Review
- Exosome miR-501-3p Elevation Contributes to Progression of Vascular Stiffness.Circulation reports · 2021Article
- Pathophysiology of Circulating Biomarkers and Relationship With Vascular Aging: A Review of the Literature From VascAgeNet Group on Circulating Biomarkers, European Cooperation in Science and Technology Action 18216.Frontiers in physiology · 2021Review
- Changes in circulating microRNA and arterial stiffness following high-intensity interval and moderate intensity continuous exercise.Physiological reports · 2020Article
- Deletion of the microRNA-degrading nuclease, translin/trax, prevents pathogenic vascular stiffness.American journal of physiology. Heart and circulatory physiology · 2019Article
- Extracellular vesicles as a novel diagnostic and research tool for patients with HTN and kidney disease.American journal of physiology. Renal physiology · 2019Review
- Epigenetic Biomarkers in Cardiovascular Diseases.Frontiers in genetics · 2019Review
- Recent research progress of microRNAs in hypertension pathogenesis, with a focus on the roles of miRNAs in pulmonary arterial hypertension.Molecular biology reports · 2018Review
- microRNA-21 and hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2018Review
- Non-Coding RNA in the Pathogenesis, Progression and Treatment of Hypertension.International journal of molecular sciences · 2018Review
- The Epigenetic Machinery in Vascular Dysfunction and Hypertension.Current hypertension reports · 2017Review
- The Role of MicroRNAs in Arterial Stiffness and Arterial Calcification. An Update and Review of the Literature.Frontiers in genetics · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) play a crucial role in myocardial and vascular remodeling and have emerged as potential diagnostic and prognostic biomarkers or as therapeutic targets. The authors aimed to investigate the expression profile of selected miRNAs in the peripheral blood of patients with well-controlled essential hypertension in relation to arterial stiffness. Expression levels of miRNAs miRNA-1, miRNA-133a, miRNA-26b, miRNA-208b, miRNA-499, and miRNA-21 in peripheral blood mononuclear cells were quantified by real-time reverse transcription polymerase chain reaction. Carotid-femoral pulse wave velocity (cfPWV) and carotid radial pulse wave velocity (crPWV) were evaluated at baseline and after 1 year of effective antihypertensive therapy. A total of 95 patients (50 men, mean age 62±9 years) with well-controlled essential hypertension were included in the analysis. Only miRNA-21 was independently correlated with changes in both cfPWV and crPWV, independently of blood pressure levels (r=-0.56 and r=-0.46, respectively; P<.001 for both). Low levels of miRNA-21 are strongly associated with an improvement in arterial stiffness in patients with well-controlled essential hypertension, independently of their blood pressure levels. These data highlight the significance of miRNA-21 in vascular remodeling and its role as a potential prognostic marker and future therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.